INFU:NYE-InfuSystems Holdings Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 6.3

Change

-0.12 (-1.87)%

Market Cap

USD 0.14B

Volume

0.13M

Analyst Target

USD 24.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.32 (+0.14%)

USD 66.94B
ALC Alcon AG

-0.51 (-0.52%)

USD 48.47B
RMD ResMed Inc

-12.85 (-5.12%)

USD 36.99B
BAX Baxter International Inc

-0.44 (-1.11%)

USD 20.54B
AVTR Avantor Inc

+0.19 (+0.71%)

USD 18.27B
TFX Teleflex Incorporated

+0.09 (+0.04%)

USD 11.63B
ATR AptarGroup Inc

+0.04 (+0.03%)

USD 10.16B
BLCO Bausch + Lomb Corp

+1.44 (+7.76%)

USD 6.55B
STVN Stevanato Group SpA

+0.68 (+3.57%)

USD 5.62B
WRBY Warby Parker Inc

-0.32 (-2.15%)

USD 1.57B

ETFs Containing INFU

FTXR First Trust Nasdaq Transp.. 6.73 % 0.60 %

+0.16 (+0.20%)

USD 0.03B
RPV Invesco S&P 500® Pure Va.. 2.28 % 0.35 %

+0.18 (+0.20%)

N/A
DVYL 2.17 % 0.00 %

N/A

N/A
ONEY SPDR® Russell 1000® Yie.. 1.18 % 0.20 %

-0.04 (0.20%)

N/A
RCD 0.00 % 0.40 %

N/A

N/A
RDIV Invesco S&P Ultra Dividen.. 0.00 % 0.39 %

-0.04 (0.20%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.23% 5% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.23% 5% F 4% F
Trailing 12 Months  
Capital Gain -35.78% 5% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.78% 5% F 5% F
Trailing 5 Years  
Capital Gain 16.67% 63% D 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.67% 56% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 9.42% 68% D+ 67% D+
Dividend Return 9.42% 68% D+ 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.32% 21% F 15% F
Risk Adjusted Return 16.72% 53% F 37% F
Market Capitalization 0.14B 29% F 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.